Poland· PL-100267881
Caprelsa
A vandetanib product containing vandetanibum, registered in Poland by Sanofi B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vandetanib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX04 (vandetanib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Vandetanib · ATC L01EX04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vandetanib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vandetanib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$239.02
The record
At a glance
URPL (Poland)- Active substance
- Vandetanibum
- Manufacturer
- Sanofi B.V.
- Country
- Poland (PL)
- ATC code
- L01EX04
- ATC class
- Vandetanib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05000283660767
- gtin05909990935444
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
351 interactions on record for vandetanib.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vandetanib · interactions on record
351 records
- 244 severe
- 95 moderate
- 12 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vandetanib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCaprelsa 300 mgEsteve Pharmaceuticals
- CzechiaCAPRELSAEsteve Pharmaceuticals S.A., Barcelona
- SpainCAPRELSA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAEsteve Pharmaceuticals S.A.
- FinlandCaprelsaEsteve Pharmaceuticals S.A.S.
- FranceCAPRELSA 300 mg, comprimé pelliculéESTEVE PHARMACEUTICALS (ESPAGNE)
- IrelandCaprelsa 300 mg film-coated tabletsEsteve Pharmaceuticals S.A.
- IcelandCaprelsaEsteve Pharmaceuticals S.A.
- NetherlandsCaprelsa, 300 mg filmomhulde tablettenEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Caprelsa
- Liechtenstein · Caprelsa
- Norway · Caprelsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/36ef66c1-1a44-4b84-abb2-554b90e6f941 GET /v1/drugs/36ef66c1-1a44-4b84-abb2-554b90e6f941?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909990935444 ¦ Rpz ¦ EU/1/11/749/002 ¦ 72572\n30 tabl.\n¦ UR/Z/4c/021/25 - 05000283660767",
"substance": "Vandetanib 300 mg",
"common_name": "Vandetanibum",
"pl_product_id": "100267881",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vandetanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.